Daily Stock List
MEDL Mobile Holdings, Inc. (MEDL)
RedChip reported earlier on MEDL Mobile Holdings, Inc. (MEDL), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.
MEDL Mobile Holdings, Inc. develops, acquires and publishes a growing library of mobile applications (apps). These apps perform particular functions for the user on the Apple and Android platforms. MEDL enters into partnerships to mobilize and monetize Intellectual Property (IP) with well-known names such as Encyclopedia Britannica, MTV's Pauly D, Cheech & Chong, Rampage Jackson and Marlee Matlin. The Company is headquartered in Fountain Valley, California.
MEDL Mobile Holdings is establishing a business model in which it expects to generate multiple revenue streams. These streams include development fees, download and in-app purchases, advertising, sponsorship, and licensing of technology. MEDL Mobile's Software Development Kit (SDK) consists of an expanding collection of tools that have been designed to help developers to better market and monetize mobile applications.
MEDL Mobile has joined forces with Specific Media to supply mobile video advertising for MEDL Mobile's earlier launched social media platform, "Hang w/." The Hang w/ platform allows live real-time video to be broadcast from one phone to many. Broadcasters earn a percentage of the advertising revenue generated based upon the number of followers who are "Hanging w/" them. Anyone with an iPhone or Android device can connect instantly to a huge base of fans via live-streaming video broadcasts.
The agreement gives Specific Media the exclusive rights to sell all unfilled advertising on the platform. MEDL Mobile Holdings retains the rights to collaborate directly with brands and advertising agencies to sell advertising and sponsorship for individual celebrities and for Hang w/ "channels" of content. MEDL is the largest shareholder of Hang With, Inc.
At the beginning of April, MEDL Mobile Holdings announced that it has been retained to create a native mobile experience for the My GI Health Patient-Provider Portal. My GI Health is a collaboration between the academic research institutions UCLA and the University of Michigan, researchers, educators, physicians, pharmaceutical companies and food and beverage companies.
MEDL Mobile Holdings, Inc. (MEDL), closed Thursday's trading session at $0.187, down 33.21%, on 4,250,814 volume with 823 trades. The average volume for the last 60 days is 269,583 and the stock's 52-week low/high is $0.12/$0.48.
Cocrystal Pharma, Inc. (COCP)
Today we are reporting on Cocrystal Pharma, Inc. (COCP), here at the QualityStocks Daily Newsletter.
Cocrystal Pharma, Inc. is a biotechnology company developing new antiviral therapeutics for human diseases. On April 16, 2014, Cocrystal Pharma announced that, effective April 15, 2014, its stock began trading under the new symbol "COCP". The updated stock trading symbol marks the successful completion of its recent merger with Biozone Pharmaceuticals, Inc., as announced on January 3, 2014. Cocrystal Pharma has its corporate headquarters in Bothell, Washington.
The Company focuses on the discovery and development of novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. It employs unique technologies and Nobel Prize winning expertise to create first- and best-in-class antivirals. The design of these technologies and Cocrystal’s market-focused approach to drug discovery are to efficiently deliver small molecule therapeutics that are safe, effective, and convenient to administer.
At present, Cocrystal Pharma has five therapeutic programs targeting the Hepatitis C Virus (HCV), Influenza Virus, the Human Rhinovirus (HRV), Dengue Virus, and the Norovirus. It is targeting two Hepatitis C replication enzymes with its Polymerase program at lead optimization stage and its Helicase program at lead identification stage. Cocrystal’s Influenza, HRV, Dengue, and Norovirus programs are targeting unmet multi-billion dollar market opportunities with first-in-class antivirals.
The Company is developing drug candidates that are specifically designed to be effective against all strains of the influenza virus and to have a high barrier to resistance. Selection of a lead compound for clinical development is planned to take place by early 2015. Regulatory filings to begin clinical studies for influenza are planned for December 2015.
Chief Executive Officer, Mr. Gary Wilcox, said, "Our drug candidates target an enzyme essential to viral replication, and should be effective against all forms of influenza, including avian influenza, an emerging public health concern in Asia. Our compounds target the endonuclease enzyme of the influenza virus, an enzyme that is a part of the influenza virus polymerase complex, and is very highly conserved among all known viral strains. We have observed that our endonuclease inhibitors bind to the highly conserved site, and inhibit enzymatic activity. These compounds appear to be active against all strains of the influenza virus.”
Cocrystal Pharma, Inc. (COCP), closed Thursday's trading session at $0.44, up 8.64%, on 378,979 volume with 68 trades. The average volume for the last 60 days is 123,553 and the stock's 52-week low/high is $0.16/$0.97.
View Systems, Inc. (VSYM)
PennyOmega, BestOtc, DrStockPick, StockHotTips, CRWEFinance, and CRWEWallStreet reported previously on View Systems, Inc. (VSYM), and we report on the Company today, here at the QualityStocks Daily Newsletter.
View Systems, Inc. is a provider of security products for schools, event planners, banks, and government institutions. The Company is a leading security technology products company with “state-of-the-art” technological solutions for modern security problems. Its products are used by commercial businesses and residential consumers wanting to monitor assets and limit liability. In essence, the Company is a manufacturer and provider of integrated ferrous and non-ferrous weapons detection systems. View Systems lists on the OTC Bulletin Board. The Company has its headquarters in Baltimore, Maryland.
View Systems manufactures and distributes products in the “Security and People Screening” category or contraband detectors. Its core product range is the “ViewScan” intelligent concealed threat detection portal encompassing pioneering proprietary technology. ViewScan is a walk-through concealed weapons detector that pinpoints weapons, and eliminates false alarms triggered by innocent metal objects. ViewScan employs a commercial laptop computer. It can be integrated with the Company’s biometric positive identification verification system.
View Systems’ Positive ID Verification System is a set of tools targeted towards checking visitors in and out of a correctional facility, courthouse, or other secured location. The package comes complete with a biometric fingerprint reader, ID scanner, and visitor badge printer. In addition, the Company’s Weapon Detection Devices product line includes the LAW Handheld Metal Detector.
Another of the Company’s products is the Visual First Responder (VFR). VFR is a first response remote video transmission system. It is used in areas where hazardous materials have been exposed. VFR is small enough to be worn on a belt, helmet or vest. It transmits conventional video or infrared imagery to the command post. It is suited for law enforcement SWAT teams, Fire Rescue units, as well as HAZMAT team operations.
This week, View Systems announced the signing of sales representation agreements with Ultimate Security Products, Inc. based in Overland Park, Kansas, and Security Marketing Consultants, Inc. (SMC) with home offices in Utica, Michigan. These agreements bring to five the number of sales rep pacts that View Systems has executed within the past 60 days. It expands the Views Systems sales representation scope by an additional 18 States.
View Systems, Inc. (VSYM), closed Thursday's trading session at $0.0161, down 0.62%, on 102,848 volume with 6 trades. The average volume for the last 60 days is 432,252 and the stock's 52-week low/high is $0.013/$0.055.
Tauriga Sciences, Inc. (TAUG)
Stock Tips Network, Stock Analyzer, PennyStocks24, Xtremepicks, Penny Stock Rumble, Wallstreetlivechat, and OurHotStockPicks reported recently on Tauriga Sciences, Inc. (TAUG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
Tauriga Sciences, Inc. is focusing on generating profitable revenues by way of license agreements and the development of a proprietary technology platform in the nano-robotics space. Its business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. It also has a pending acquisition in the cannabis space. The Company previously went by the name Immunovative, Inc. It changed its name to Tauriga Sciences, Inc. in March of 2013. The Company’s shares trade on the OTC Markets’ OTCQB.
The Company has been working to establish an international presence through partnerships and global exclusive licenses, because its proprietary BactoBot technology can potentially address many global water related issues. On January 28, 2014, Tauriga Sciences announced that it completed the acquisition of Cincinnati, Ohio based synthetic biology pioneer Pilus Energy, LLC. Pilus Energy will operate as a wholly owned subsidiary of Tauriga Sciences. This is pursuant to the terms of the definitive agreement. Pilus will maintain its headquarters location in Ohio.
Pilus Energy is a developer of alternative cleantech energy platforms employing proprietary microbial solutions that creates electricity while consuming polluting molecules from wastewater. In the process, the technology generates electricity and produces economically important gases and chemicals. Pilus Energy licenses a low-cost, scalable electrogenic bioreactor platform and wastewater-to-value BactoBots. Pilus Energy will also gain additional revenues from carbon and renewable energy credits (REC).
Recently, Tauriga Sciences disclosed to shareholders that it entered into the March 11, 2014 definitive merger agreement with Oakland, California based Honeywood LLC, an affiliate of Doc Green's Healing Collective. Honeywood has been researching and developing cannabis based healing products since 2010. Its primary business models and industry capabilities include the ability to manufacture medicinal Cannabis based products, the licensing of brands and delivery technologies, and the infrastructure to provide valuable laboratory services to the rapidly growing medicinal cannabis industry.
This week, Tauriga Sciences announced that Mr. Lawrence A. May, M.D., F.A.C.P. has accepted the position of Chief Medical Officer (CMO). Dr. May brings a unique combination of clinical, scientific and business experience. Before becoming CMO, Dr. May served on Tauriga's Medical Advisory Board and has been advising the Company on developing products in the natural medicine market.
Tauriga Sciences, Inc. (TAUG), closed Thursday's trading session at $0.0445, down 1.11%, on 3,378,648 volume with 135 trades. The average volume for the last 60 days is 9,482,376 and the stock's 52-week low/high is $0.0035/$0.1075.
InsPro Technologies Corp. (ITCC)
We are highlighting InsPro Technologies Corp. (ITCC) today, here at the QualityStocks Daily Newsletter.
InsPro Technologies Corp. (through its subsidiary, InsPro Technologies, LLC) offers InsPro Enterprise. This is an end-to-end, web-based policy administration system used by insurance carriers and third-party administrators. The Company is a leading provider of Life and Health core policy administration software, which allows insurance carriers and third-party administrators to rapidly respond to evolving market needs, improve customer service, and reduce operating costs. InsPro Technologies is based in Eddystone, Pennsylvania.
The Company offers its solutions via standard software licensing, as a hosted solution, or through Software as a Service (SaaS) delivery. Customers can manage the entire product and policy lifecycle on a single integrated platform. InsPro Enterprise is a single technology solution used to manage all insurance processing requirements supporting multiple product lines and hybrid products for group and individual policies on a single web-based platform.
The InsPro Enterprise design provides carriers the option to install the solution as an end-to-end straight through processing suite or on a modular, componentized basis to address immediate areas of concern. The InsPro Enterprise suite includes Product Configuration Workbench, New Business and Underwriting, Billing and Collections, Policy Administration, Agent Management and Commissions, Claims, Document Management, Web Portals, as well as Data Analytics components.
Recently, InsPro Technologies announced its financial results for the quarter and year ended December 31, 2013. Revenues decreased 8 percent to $3,055,850 in the fourth quarter of 2013, versus $3,311,087 in the fourth quarter of 2012. This was because of lower implementation services for new clients partially counterbalanced by increased ASP/Hosting and maintenance revenues.
Revenues increased 22 percent to $14,802,268 in 2013, versus $12,146,237 in 2012. This was mainly because of $2,550,000 of license fees recognized upon the completion of the implementation of InsPro Enterprise for three clients combined with increased ASP/Hosting and maintenance revenues.
Net loss was $833,814 in the fourth quarter of 2013, versus a net loss of $1,018,366 in the fourth quarter of 2012. Net loss was $1,743,008 in 2013, versus a net loss of $7,883,145 in 2012.
InsPro Technologies Corp. (ITCC), closed Thursday's trading session at $0.087, down 48.82%, on 646,651 volume with 162 trades. The average volume for the last 60 days is 133,959 and the stock's 52-week low/high is $0.03/$0.49.
Zenosense, Inc. (ZENO)
The QualityStocks Daily Newsletter would like to spotlight Zenosense, Inc. (ZENO). Today, Zenosense, Inc. closed trading at $0.64, even for the day, on 11,650 volume with 12 trades. The stock’s average daily volume over the past 60 days is 14,475, and its 52-week low/high is $0.50/$1.00.
Zenosense, Inc. (ZENO) is developing and intends to market a novel device to enable hospitals to detect Methicillin-resistant Staphylococcus Aureus (MRSA) bacterial contamination, a major constituent of Hospital Acquired Infections (HAIs). The annual costs of treating hospitalized MRSA patients are estimated to be between $3.2 billion and $4.2 billion in the United States alone. MRSA infected patients are likely to spend three times as long in a hospital stay at three times the cost, and are five times more likely to die than an uninfected patient.
Early detection of MRSA and HAIs in general is vital. Recent studies suggest that implementing prevention practices can lead to up to a 70 percent reduction in certain HAIs with a financial benefit of using these prevention practices estimated to be as high as $25.0 billion to $31.5 billion in medical cost savings in the United States alone (according to a report by the Centers for Disease Control and Prevention, part of the US Department of Health and Human Sciences). Currently, no cost effective early detection device is available.
The Zenosense MRSA detection device is expected to act like a “smoke detector” for MRSA; designed to detect MRSA in the environment or infected patient, even before a patient demonstrates any obvious symptoms, satisfying this huge unmet need.
Zenosense has an agreement with leading European sensor developer Sgenia Group, which is developing such a device exclusively for Zenosense through their subsidiary Zenon Biosystem. The estimated manufacturing cost per device is under $100 USD and possibly as low as $50 USD. The Zenosense device, utilizing established Sgenia programming and patent-pending hardware, utilizes a single sensor to perform an infinite number of scans, creating tens of thousands of "virtual sensors". The low cost and compact design of the Zenosense device, if successfully developed, would make it possible to be worn by individuals, as well as placed in numerous sensitive areas in the healthcare setting.
Zenosense has a streamlined management team experienced in high-level marketing in the medical sector, supported by the outsourced Zenon Biosystem scientific/development team of qualified personnel with extensive knowledge and experience in the development of sensors. Both of these teams will fuse together through a high level advisory board of experienced professionals. A cost-effective Zenosense MRSA detection device, once developed, is expected to be in high demand, driven by patient safety, cost and insurance considerations. Disclaimer
Zenosense, Inc. Company Blog
Zenosense, Inc. News:
Zenosense, Inc. Enters Into $475,000 Securities Purchase Agreement
Zenosense, Inc. Launches New Company Website
P2 Solar, Inc. (PTOS)
The QualityStocks Daily Newsletter would like to spotlight P2 Solar, Inc. (PTOS). Today, P2 Solar, Inc. closed trading at $0.0499, up 4.61%, on 6,000 volume with 1 trade. The stock’s average daily volume over the past 60 days is 74,705, and its 52-week low/high is $0.0122/$0.08.
P2 Solar, Inc. today announces that an Implementation Agreement has been signed with Punjab Energy Development Agency (PEDA), Punjab State's governing authority on all renewable projects.The signing of this agreement grants permissions to the Company to establish, operate, and maintain the project on a Build, Own, and Operate basis, as well as allows for the non-consumptive use of the canal water for the purpose of power generation during the initial agreement period of thirty five years.
P2 Solar, Inc. (PTOS) participates in the lucrative renewable energy market as a developer of solar photovoltaic (PV) power projects, focusing its initiatives on “sunbelt” areas where sunlight exposure is abundant; renewable energy policies are favorable; public and private sectors are actively seeking to incorporate solar PV into their electricity consumption profiles; and where governments offer attractive subsidies to motivate development.
Acknowledging rising demand for clean energy worldwide, solar PV power’s increasingly competitive edge over grid electricity, and commercial efforts to reduce reliance on greenhouse gas emitting fossil fuels, P2 Solar invests and channels its resources to benefit from these global trends.
The company’s growth strategy centers on management’s aggressive mandate to develop 150 MWp of electricity generating capacity in several phases over the next few years. To this accord, the company is focused on further development of its project portfolio, which currently consists of the Langley Rooftop Project in British Columbia; the Rajgarh Mini-hydro Project in Punjab, India; and the Tibba Mini-hydro Project, also located in Punjab India.
Backed by executive leadership with more than 60 years of combined experience, P2 Solar continues to develop and expand its current projects while opportunistically pursuing development opportunities in other regions with favorable solar energy regimes, including Eastern Europe and Canada. Disclaimer
P2 Solar, Inc. Company Blog
P2 Solar, Inc. News:
P2 Solar Signs Implementation Agreement for Rajgarh Hydro Project
P2 Solar Receives Government Approval for Rajgarh Hydro Project
P2 Solar Acquires Its Second Renewable Energy Project in India
Kallo, Inc. (KALO)
The QualityStocks Daily Newsletter would like to spotlight Kallo, Inc. (KALO). Today, Kallo, Inc. closed trading at $0.09, up 9.22%, on 44,800 volume with 4 trades. The stock’s average daily volume over the past 60 days is 228,711, and its 52-week low/high is $0.0126/$0.45.
Kallo, Inc. (KALO) leverages a suite of technologies to improve the quality and efficiency of care in the $6.3 trillion global healthcare industry. Offering centralized, congruent solutions that attend healthcare and business issues, the company addresses the needs of hospitals, ministries of health, physicians, and other healthcare organizations.
As a result of an expanding and aging population, coupled with an increasing number of people suffering from chronic diseases and lifestyle related conditions, healthcare expenditures continue to grow. Kallo is focused on introducing new healthcare technology that helps contain costs, enable better methods to monitor/treat medical conditions, and increase the reach of healthcare providers to remote areas.
The tailored solutions offered by Kallo complement existing infrastructure, workflows, and processes, increasing both uptime and productivity. The company’s suite of products complies with international, national, and regional standards, and its stringent quality control ensures repeatable, process-driven delivery for maximum performance.
Kallo’s executives and directors bring rich and diverse industry knowledge. Collectively, the management team reflects the strength of the company’s global network and the diversity of its global culture. The team’s entrepreneurship, passion, experience, and knowledge of healthcare enables Kallo to continually deliver higher standards. Disclaimer
Kallo, Inc. Company Blog
Kallo, Inc. News:
Kallo Inc. - Announces Appointment of Two Senior Managers
Update on US $200,000,925.00 Supply Contract for Kallo MobileCare and RuralCare in Guinea
Kallo Inc. Selects Dell to Provide Technology Infrastructure for Global Healthcare Initiative
Pan Global Corp. (PGLO)
The QualityStocks Daily Newsletter would like to spotlight Pan Global Corp. (PGLO). Today, Pan Global Corp. closed trading at $0.11, up 4.76%, on 54,737 volume with 16 trades. The stock’s average daily volume over the past 60 days is 359,585, and its 52-week low/high is $0.09/$0.96.
Pan Global Corp. (PGLO) is focused on building the world’s green economy by developing, building, owning, and operating the necessary infrastructure. Current opportunities are currently concentrated on developing projects in India, specifically in the areas of hydro-power generation, solar PV, geo-thermal, sustainable agriculture, and green construction.
The India growth story is frequently compared to China, which has sustained above-average annual growth for three decades, whereas India’s take-off growth began at a later stage. During the last decade, India’s growth has averaged approximately 8% per year. India is poised for high GDP growth that will be sustained for decades to come.
Within the Indian market there are available various government-backed incentives programs, including those which provide direct tariff subsidies as well as market-based tariff support through renewable energy credits. Assessing project viability on a case by case basis, Pan Global seeks to invest in projects both as owner-developers and/or as partners with other developers.
Pan Global’s business strategy is an extension of the company’s commitment to improve human well-being and social equity, while significantly reducing environmental risks and ecological scarcities. By developing a series of highly environmentally sustainable and high ROI projects, Pan Global aims to accelerate business growth. Disclaimer
Pan Global Corp. Company Blog
Pan Global Corp. News:
Pan Global, Corp. Provides Part E of Shareholders Analysis Series -- Project Badyar Annual Revenues Forecasted to Be Approximately $1.95 Million USD for 35 Years
Pan Global, Corp. Provides Part D of Shareholders Analysis Series -- Project Badyar to Earn 4.27 INR ($0.0709 USD) per Kilowatt Hour Under Power Purchase Agreement With India's State-Owned Power Corporation
Pan Global, Corp. Increases Equity Stake in Small-Hydro Plant in Northern India
Consorteum Holdings, Inc. (CSRH)
The QualityStocks Daily Newsletter would like to spotlight Consorteum Holdings, Inc. (CSRH). Today, Consorteum Holdings, Inc. closed trading at $0.0078, up 4.00%, on 107,500 volume with 7 trades. The stock’s average daily volume over the past 60 days is 274,364, and its 52-week low/high is $0.004/$0.031.
Consorteum Holdings, Inc. (CSRH) utilizes the most technically advanced global solutions available today. By working with a multitude of global technologies, Consorteum is able to create customized programs for maximum results. This approach enables unparalleled flexibility when sourcing solutions, resulting in smarter, faster deployment of technologies, competitive pricing, and potential for new streams of revenue.
Through its exclusive software license with Tarsin Inc., the company leverages a team of software developers that understands the complexities of delivering digital media content across mobile handsets. Tarsin is capable of providing clients with integration and support for over 700 mobile carriers globally on a seamless and secure platform to take advantage of the increasing demand for rich mobile content.
Consorteum's flagship CAPSA technology platform brings a universal solution to the problems of wagering and betting on mobile devices. Multiple different operating systems, user interfaces, and form factors have created enormous barriers to launching commercial initiatives. But with CAPSA, gaming operators can now cost-effectively monetize innovative mobile wagering products and services quickly and robustly.
In addition to its mobile initiatives, Consorteum is also actively engaged in the financial industry, providing MasterCard solutions as well as loyalty and reward programs. The company has strategically designed its business initiatives to create repetitive transactions on an ongoing basis. Consorteum's goal is to have their customers think of them more as partners, rather than just technology providers, for longer-lasting, more profitable relationships. Disclaimer
Consorteum Holdings, Inc. Company Blog
Consorteum Holdings, Inc. News:
Consorteum Holdings Signs Mobile Application Development and Business Deal With Bet Butler Limited
Consorteum Holdings Inc. Announces ThreeFiftyNine's New Partner Program
Consorteum Holdings Inc. and The Alternative Initiate New Brand Development Project
Today's Top 3
Fast Money Alerts
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Armco Metals Holdings, Inc. (AMCO) Enters Into Agreement to Acquire 100% of Draco Resources, Inc.
- Colt Resources Inc. (COLTF) provides Operational Update on Portuguese projects
- Consorteum Holdings, Inc. (CSRH) Signs Mobile Application Development and Business Deal With Bet Butler Limited
- eCrypt Technologies, Inc. (ECRY) Appoints Former Microsoft Engineer to Advisory Board
- Global Payout, Inc. (GOHE) Security Enhancement Moves by Target Corp. to Include Chip and PIN Technology Lauded by Global Payout
- Great Plains Holdings, Inc. (GTPH) Completes Final Phase of Real Estate Asset Project Ahead of Schedule
- Infinite Group, Inc. (IMCI) Cybersecurity In Focus At IMCI With New Hire
- Innocent, Inc. (INCT) Announces Letter to Shareholders
- International Stem Cell Corp. (ISCO) Announces Positive Parkinson's Disease Data
- Kallo, Inc. (KALO) Announces Appointment of Two Senior Managers
- Mabwe Minerals Inc. (MBMI) Raptor Resources Holdings Issues Update on the Derbyshire Stone Quarry
- NeuroMama, Ltd. (NERO) CES Event Showcasing Intelligent Search Engine, Online Retail Platform and Advertising Opportunities, Reception Act Performer Fall and Serious Injuries Documented
- NutraNomics, Inc. (NNRX) Discusses Long-Term Global Expansion Strategy with UNO International Corp.
- P2 Solar, Inc. (PTOS) Signs Implementation Agreement for Rajgarh Hydro Project
- Pan Global Corp. (PGLO) Provides Part E of Shareholders Analysis Series -- Project Badyar Annual Revenues Forecasted to Be Approximately $1.95 Million USD for 35 Years
- Raptor Resources Holdings Inc. (RRHI) Issues Update on the Derbyshire Stone Quarry
- Start Scientific, Inc. (STSC) is “One to Watch”
- Victory Energy Corp. (VYEY) Engages Euro Pacific Capital
- VistaGen Therapeutics, Inc. (VSTA) Receives Notice of Allowance for U.S. Patent Expanding Stem Cell Technology Platform for Drug Rescue and Regenerative Medicine
- Well Power Inc. (WPWR) Corporate Update
- Zenosense, Inc. (ZENO) Enters Into $475,000 Securities Purchase Agreement